Advanced Accelerator Applications
| Advanced Accelerator Applications SA | |
|---|---|
| legal form | SA |
| founding | 2002 |
| Seat |
Saint-Genis-Pouilly , France
|
| management | Sidonie Golombowski-Daffner |
| Branch | pharmacy |
| Website | www.adacap.com |
Advanced Accelerator Applications , or AAA for short, is a pharmaceutical company specializing in the field of nuclear medicine . The group operates in all three segments of molecular nuclear medicine (PET, SPECT and therapy) for the diagnosis and treatment of serious diseases in the areas of oncology (cancer), neurology , cardiology , infectious diseases and inflammatory diseases.
history
AAA was founded in 2002 by the Italian physicist Stefano Buono as a spin-off from the European Organization for Nuclear Research ( CERN ). The first day of trading was November 11, 2015.
The group currently operates 21 manufacturing facilities as well as research and development facilities that manufacture both diagnostic and therapeutic nuclear medicine products, and has a workforce of more than 530 employees in 13 countries ( France , Italy , Great Britain , Germany , Switzerland , Spain , Belgium , Netherlands , Poland , Portugal , Israel , the USA and Canada).
AAA founder is Stefano Buono. The AAA Board of Directors includes Frédéric Collet, Jessica Toepfer and Susanne Schaffert.
In October 2017, Novartis announced that it would acquire the company for US $ 3.9 billion.
The acquisition was completed on January 22, 2018.
Products
AAA has a product portfolio for diagnostic and therapeutic applications in the areas of molecular imaging and therapy. The group's portfolio ranges from radioactive materials for positron emission tomography (PET) to diagnostic products for single photon emission computed tomography (SPECT).
pipeline
AAA has a wide range of development products. The company's main development product is Lu-Dotatate (Lutathera), a phase III therapeutic cancer product that was developed for the treatment of certain gastro-entero-neuroendocrine tumors of the pancreas (GEP-NET). It selectively recognizes over-expressed somatostatin receptors, while at the same time the gamma emissions enable the visualization and localization of the drug or tumor via tomographic measurements.
Another AAA development product is a radiopharmaceutical gallium -68 dopatate derivative (Somakit), which was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the diagnostic assessment of GEP-NET tumors in early 2014 Has received orphan drug status.
Individual evidence
- ↑ HBM Healthcare Investments participates with EUR 20 million in the financing round of Advanced Accelerator Applications ( Memento from December 5, 2014 in the Internet Archive ) (PDF)
- ↑ Insider Monkey Stocks Hot on the Market on Wednesday 11 November.
- ↑ adacap.com: About Us , accessed January 16, 2017.
- ↑ Wirtschaftswoche: Advanced Accelerator Applications: Novartis buys cancer specialists for $ 3.9 billion. Retrieved June 22, 2019 .
- ↑ Novartis completes tender offer for Advanced Accelerator Applications SA and announces commencement of subsequent offering period Novartis press release of January 22, 2018, accessed on December 1, 2019
- ↑ Pharma-Seitung, Das Pharma Portal, GE Healthcare signs first contract for the development of pan-European production capacities for PET tracers, 17/10/11
- ↑ First pivotal Phase III study evaluating 177Lu-Dotatate in midgut neuroendocrine tumors ( Memento from December 5, 2014 in the Internet Archive ) ( English )
- ↑ Clinical Leader: FDA And EMA Grant Orphan Drug Status To AAA's Gallium-68 DOTATATE